Certain products developed according to strict pharmaceutical guidelines have been redesigned to fulfill nutraceutical needs on the market.
AXIM is actively involved in the research and development of innovative pharmaceutical delivery systems and active pharmaceutical ingredients (API).
AXIM has 5 issued patents and 12 more filed, as well as 28 trademarks in its Intellectual Property Portfolio
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy.
AXIM® Biotechnologies, Inc. is a world leader in research and development of cannabinoid-based pharmaceutical products.
AXIM is developing a broad IP portfolio covering diverse aspects of both technology and clinical indications. Clinical development programs cover diverse indications including diseases with currently unmet or poorly met treatment needs and providing solutions with potentially significantly reduced side effects to the currently available ones.